Equities research analysts forecast that Biolife Solutions (NASDAQ:BLFS) will report sales of $3.81 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Biolife Solutions’ earnings, with the lowest sales estimate coming in at $3.80 million and the highest estimate coming in at $3.81 million. Biolife Solutions posted sales of $2.37 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 60.8%. The business is expected to report its next earnings report on Thursday, May 10th.
On average, analysts expect that Biolife Solutions will report full year sales of $3.81 million for the current year. For the next financial year, analysts expect that the company will report sales of $20.29 million per share, with estimates ranging from $20.00 million to $20.57 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Biolife Solutions.
Biolife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, March 8th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $3.13 million during the quarter, compared to the consensus estimate of $3.10 million. Biolife Solutions had a negative net margin of 22.82% and a negative return on equity of 37.37%.
BLFS stock opened at $7.17 on Friday. The company has a market capitalization of $97.46, a P/E ratio of -34.14 and a beta of 0.37. Biolife Solutions has a 12-month low of $2.01 and a 12-month high of $7.53.
In other Biolife Solutions news, CEO Michael Rice sold 12,540 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $5.57, for a total transaction of $69,847.80. Following the completion of the sale, the chief executive officer now directly owns 152,057 shares in the company, valued at approximately $846,957.49. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders have sold 37,620 shares of company stock valued at $201,894. Company insiders own 36.80% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Essex Investment Management Co. LLC raised its stake in Biolife Solutions by 199.8% during the 4th quarter. Essex Investment Management Co. LLC now owns 254,096 shares of the medical equipment provider’s stock valued at $1,525,000 after buying an additional 169,341 shares during the last quarter. Wells Fargo & Company MN purchased a new stake in shares of Biolife Solutions in the 4th quarter worth $111,000. Finally, Millennium Management LLC increased its stake in shares of Biolife Solutions by 901.6% in the 4th quarter. Millennium Management LLC now owns 182,550 shares of the medical equipment provider’s stock worth $1,095,000 after purchasing an additional 164,324 shares in the last quarter. Institutional investors and hedge funds own 12.11% of the company’s stock.
WARNING: “Biolife Solutions (BLFS) Expected to Announce Quarterly Sales of $3.81 Million” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3340146/biolife-solutions-blfs-expected-to-announce-quarterly-sales-of-3-81-million.html.
Biolife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biolife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.